The results strengthen the case for rapid, durable symptom relief in a condition with significant unmet need.
Positive Phase 2a data from EnteroBiotix marks a major milestone for its oral, full-spectrum microbiome therapy for IBS.
The results strengthen the case for rapid, durable symptom relief in a condition with significant unmet need.